Seeds J W, Peng T C
Department of Obstetrics and Gynecology, Maternal and Fetal Medicine Section, Virginia Commonwealth University/Medical College of Virginia, Richmond USA.
Am J Obstet Gynecol. 2000 Aug;183(2):316-22; discussion 322-3. doi: 10.1067/mob.2000.107656.
Our purpose was to examine the risk of fetal death associated with augmented fetal growth.
All live births recorded in Virginia between January 1, 1991, and December 31, 1993, were examined. Mortality rates were examined for infants born at or beyond 24 weeks' gestational age with weights between the 75th and 90th percentiles, from the 90th to the 95th percentile, and >95th percentile.
Mortality rates were found to rise only slightly with birth weights >90th percentile. A recorded diagnosis of maternal diabetes, however, was associated with a significant risk in the presence of augmented fetal growth. Augmented fetal growth without maternal glucose intolerance showed no increase in mortality.
Augmented fetal growth in the absence of maternal glucose intolerance appeared not to be associated with a significant increase in the risk of death among these births. Increased risk was found when augmented fetal growth was associated with maternal diabetes.
我们的目的是研究与胎儿生长加速相关的胎儿死亡风险。
对1991年1月1日至1993年12月31日在弗吉尼亚州记录的所有活产进行检查。对孕周24周及以上、体重在第75至90百分位数之间、第90至95百分位数之间以及大于第95百分位数的婴儿的死亡率进行检查。
发现出生体重高于第90百分位数时死亡率仅略有上升。然而,记录的母亲糖尿病诊断在胎儿生长加速的情况下与显著风险相关。没有母亲葡萄糖不耐受的胎儿生长加速并未显示死亡率增加。
在没有母亲葡萄糖不耐受的情况下,胎儿生长加速似乎与这些出生时的死亡风险显著增加无关。当胎儿生长加速与母亲糖尿病相关时,发现风险增加。